Non-structural protein 13 helicase (nsp13)

SARS-CoV-2 non-structural protein 13 (nsp13) is a multifunctional enzyme essential for the replication and transcription of the viral genome [6, 12]. It belongs to the superfamily 1B (SF1B) of helicases and catalyzes the unwinding of double-stranded RNA or DNA in a 5' to 3' direction, powered by the hydrolysis of nucleoside triphosphates (NTPs) [4, 14]. In addition to its helicase and NTPase activities, nsp13 possesses RNA 5'-triphosphatase activity, which is a critical step in the formation of the viral mRNA cap structure [12, 13]. The protein is highly conserved across the Coronaviridae family, sharing over 99% sequence identity with the nsp13 of SARS-CoV, making it an attractive target for broad-spectrum antiviral therapies [1, 16]. Beyond its enzymatic roles, nsp13 interacts with the viral RNA-dependent RNA polymerase (nsp12) to form the replication-transcription complex and acts as an innate immune antagonist by facilitating the degradation of host TANK-binding kinase 1 (TBK1) [7, 15]. Current drug discovery efforts focus on small-molecule inhibitors that target the ATP-binding pocket or the RNA-binding channel to disrupt viral propagation [2, 5]. Targeting nsp13 is considered a strategic approach to overcome resistance seen in other viral proteins and represents a high-priority therapeutic target for managing COVID-19 [3, 11].

Other names

nsp13nsp13-HELSARS-CoV-2 helicaseRNA helicase nsp13NTPase/helicaseNon-structural protein 13

Inhibition of ATPase activity [1, 14], inhibition of RNA unwinding [14, 16], disruption of the replication-transcription complex [13], and competitive binding at the ATP-binding site [2].